Literature DB >> 21309722

A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases.

Concetto Regalbuto1, Pasqualino Malandrino, Andrea Tumminia, Rosario Le Moli, Riccardo Vigneri, Vincenzo Pezzino.   

Abstract

BACKGROUND: The diffuse sclerosing variant of papillary thyroid carcinoma (DSPC) is a relatively rare variant of papillary thyroid cancer. Large studies of patients with DSPC have been infrequently performed, and controversy still exists concerning some DSPC features and outcomes. The aim of the present study was to retrospectively evaluate the clinicopathologic features and outcomes in a series of 34 consecutive patients with DSPC and to compare them with a larger group of 245 consecutive patients with the classic variant of papillary thyroid carcinoma (cPTC) that were evaluated in the same period. PATIENTS AND METHODS: Clinical and histological features (sex, age, tumor size,multifocality, bilaterality, extra thyroid extension, and local and distant metastases) were recorded in all patients, as well as any persistent or recurrent disease and the patients' disease status at last observation. Patients with cPTC were classified as either low (122) or high risk (123). DSPC and high-risk patients were all treated with the same protocol, including ¹³¹I treatment. All patients were included in a Cox regression model analysis to investigate the effect of each variable on the hazard ratio.
RESULTS: As expected, multifocality, bilaterality, and extra thyroid extension were more frequently noted at presentation, and the pT1 category of TNM classification was less frequently noted in DSPC and high-risk patients with cPTC compared with low-risk patients with cPTC. No significant difference was found between patients with DSPC and those with high-risk cPTC, except that extra thyroid extension was found more frequently in the patients with DSPC. Using multivariate analysis, diffuse sclerosing variant was an independent variable for predicting a high risk of persistent and recurrent disease during initial follow-up. However, at a later time, and after further treatment, the disease status was not different between patients with DSPC and those with high-risk cPTC, and only the presence of distant metastases affected the final outcome.
CONCLUSIONS: DSPC is a thyroid papillary carcinoma variant characterized by high aggressiveness. In patients with DSPC, the outcome is worse than in patients with low-risk cPTC; and, at presentation, characteristics are somewhat worse than for patients with high-risk cPTC.At medium term, the outcome is similar to that observed in patients with high-risk cPTC, provided aggressive treatment is used (additional surgical intervention, when required, and/or ¹³¹I radiotherapy).

Entities:  

Mesh:

Year:  2011        PMID: 21309722     DOI: 10.1089/thy.2010.0331

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  22 in total

1.  Clinicopathologic features and outcomes in patients with diffuse sclerosing variant of papillary thyroid carcinoma.

Authors:  Junko Akaishi; Kiminori Sugino; Kaori Kameyama; Chie Masaki; Kenichi Matsuzu; Akifumi Suzuki; Takashi Uruno; Keiko Ohkuwa; Hiroshi Shibuya; Wataru Kitagawa; Mitsuji Nagahama; Kazuo Shimizu; Koichi Ito
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

Authors:  F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti
Journal:  J Endocrinol Invest       Date:  2018-05-04       Impact factor: 4.256

4.  Surgical Management of Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma. Experience in 25 Patients.

Authors:  Claudio Spinelli; Silvia Strambi; Sohail Bakkar; Andrea Nosiglia; GianMarco Elia; Alessia Bertocchini; Chiara Calani; Matteo Leoni; Riccardo Morganti; Gabriele Materazzi
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

5.  Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods.

Authors:  M Russo; P Malandrino; M Moleti; F Vermiglio; M A Violi; I Marturano; E Minaldi; R Vigneri; G Pellegriti; C Regalbuto
Journal:  J Endocrinol Invest       Date:  2017-05-20       Impact factor: 4.256

6.  Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes.

Authors:  Sadana Balachandar; Michael La Quaglia; R Michael Tuttle; Glenn Heller; Ronald A Ghossein; Charles A Sklar
Journal:  Thyroid       Date:  2016-02       Impact factor: 6.568

7.  Survival of aggressive variants of papillary thyroid carcinoma in patients under 55 years old: a SEER population-based retrospective analysis.

Authors:  Jianhua Feng; Fei Shen; Wensong Cai; Xiaoxiong Gan; Xingyan Deng; Bo Xu
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

8.  Shear wave elastography diagnosis of the diffuse sclerosing variant of papillary thyroid carcinoma: A case report.

Authors:  Nianyu Xue; Youfeng Xu; Pintong Huang; Shengmin Zhang; Hongwei Wang; Fei Yu
Journal:  Mol Clin Oncol       Date:  2016-06-13

9.  Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis.

Authors:  Eric J Kuo; Paolo Goffredo; Julie A Sosa; Sanziana A Roman
Journal:  Thyroid       Date:  2013-09-14       Impact factor: 6.568

10.  Prognostic Impact of Histologic Grade for Papillary Thyroid Carcinoma.

Authors:  Allen S Ho; Michael Luu; Laurel Barrios; Bonnie L Balzer; Shikha Bose; Xuemo Fan; Evan Walgama; Jon Mallen-St Clair; Usman Alam; Iram Shafqat; De-Chen Lin; Yufei Chen; Jennifer E Van Eyk; Ellie G Maghami; Glenn D Braunstein; Wendy L Sacks; Zachary S Zumsteg
Journal:  Ann Surg Oncol       Date:  2020-08-17       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.